November 9, 2015
Clinical trial: Neurocognitive markers of affective and psychotic disorders
Many people experience a combination of psychotic and mood symptoms that change over time, and often do not fit neatly into the diagnostic categories of ‘schizophrenia’ or ‘bipolar disorder’. more...
Australian Journal of Pharmacy
November 3, 2015
New atypical antipsychotic for schizophrenia has ‘negligible’ weight effect
Prof David Castle from Melbourne says one of the challenges that clinicians face in treating schizophrenia with medication is unwanted weight gain and changes in metabolic profile. “The implications of excessive weight gain mustn’t be overlooked. Treating the mind should not be at the expense of the body.” Latuda (lurasidone HCl) will be avail on PBS from 1 Nov. more...
November 6, 2015
New study identifies better option for some people with treatment-resistant schizophrenia
Patients who don't respond to standard antipsychotic medications for schizophrenia have better outcomes if they begin taking the drug clozapine, an atypical antipsychotic drug, instead of moving on to another standard antipsychotic, says new study.more...
Medical News Today
November 7, 2015
Antipsychotic drugs linked to brain tissue loss in patients with schizophrenia
University of Brescia (Italy) study found that the long-term use of first-generation antipsychotics was associated with greater progressive loss of gray matter, while the use of second-generation medications "did not correlate with GM [gray matter] volume changes over time and was not associated with cortical tissue loss." more...
5 February, 2014
Schizophrenia: Time to Flush the Meds?
Cognitive Behaviour Therapy (CBT) may be a better option for some patients. more...